AHA 2016

The American Heart Association Scientific Sessions will bring together cardiovascular experts to present cutting-edge research on a wide array of heart-related topics. The Sessions will be held November 12-16, 2016, in New Orleans, Louisiana. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.

Coverage

Dr Roxana Mehran Discusses the Outcomes of the PIONEER AF Study
   |    AHA 2016
The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
   |    AHA 2016 > Mary Caffrey
A study inspired by a patient who could not afford his heart medication shows that there was no pattern to price variability for a common regimen to treat heart failure, which could contribute to poor adherence.
   |    AHA 2016 > Michael R. Page, PharmD, RPh
The study now includes 494 patients, and will be complete when 503 are enrolled. Of the participants, 60% required anticoagulant reversal to undergo surgery.
   |    AHA 2016 > Mary Caffrey
For some time, cardiologists have wondered whether there was anything to be gained by pushing LDL or "bad" cholesterol to very low levels.
   |    AHA 2016 > Mary Caffrey
A study of a pair of large databases shows a strong link between obesity and heart failure.
   |    AHA 2016 > Mary Caffrey
The study finds one-quarter of the patients stop taking anticoagulants within 3 months and nearly three-quarters have stopped after 2.25 years.
   |    AHA 2016 > Michael R. Page, PharmD, RPh
Presenters noted that this was an important but unusual trial, because it examined drugs not in isolation but how they are used in combination.
   |    AHA 2016 > Mary Caffrey
The results point to the need for more study on the effects of long-duration blood pressure treatment to prevent cognitive decline, especially in the highest risk patients.
Compendia
COPD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST
Upcoming Partner Events
August 16-17, 2017
Philadelphia, PA
October 24-25, 2017
San Francisco, CA
$vacMongoViewPlus$